Uncover novel drug targets and resistance mechanisms with genome-scale precision

CRISPR Functional Genomics Screening

DuneX Biosciences provides comprehensive CRISPR screening services to identify gene dependencies, synthetic lethal interactions, and phenotypic drivers of drug response. Our platform integrates genome-wide knockout or activation libraries with high-content readouts and next-generation sequencing.

Workflow Overview

We handle the complete process — from construct design through assay-ready, cryopreserved vials.

Step 1 — Library Design & Construction

Genome-wide or focused sgRNA libraries (10⁵–10⁶ guides) built for knockout, CRISPRi, or CRISPRa screens.

Step 2 — Cell Line Engineering

Lentiviral transduction or stable Cas9/Cas12a cell line generation with optimized MOI and selection.

Step 3 — Screening Execution

Drug-treated vs. control, proliferation-based, or FACS-based phenotypic enrichment workflows.

Step 4 — Genomic DNA Extraction

Isolate high-quality genomic DNA from input and selected cell populations.

Step 5 — NGS & Quantification

Amplify sgRNA cassettes for Illumina sequencing and quantify guide abundance.

Step 6 — Hit Analysis & Interpretation

MAGeCK / CRISPResso2 pipeline to identify gene dependencies, resistance mechanisms, and key drivers.

Package Pricing

Drug Synthetic Lethal Screen

Identify genes whose loss enhances or suppresses sensitivity to a specific therapeutic compound. This route is ideal for target identification, mechanism-of-action elucidation, and drug combination discovery.

4,999

/sample

Genome-wide or custom sgRNA library (10⁵–10⁶ guides)

Drug-treated vs. control cell populations

NGS-based dropout or enrichment analysis (MAGeCK / CRISPResso2)

Hit prioritization and pathway enrichment mapping

** Minimum 2 Samples: Drug treated vs untreated

💡 Deliverables: ranked gene lists, volcano plots, pathway analyses, and validation-ready hit data.

FACS-Based Phenotypic Screen

Discover genetic drivers of surface marker expression, signaling activity, or cell fate using fluorescence-activated cell sorting (FACS) as the selection readout. Ideal for immunology, oncology, and cell therapy programs.

6,999

/sample

***

CRISPR knockout / activation libraries in mammalian cells

Sorting based on fluorescent reporter intensity or antibody staining

Sorted population sequencing and differential sgRNA enrichment

Data integration with single-cell expression or pathway analysis

*** Minimum 2 Samples: Low expression vs high expression

🔬 Deliverables: FACS gating data, differential gene lists, and pathway enrichment reports.

Drug Synthetic Lethal Screen

4,999

/sample

Genome-wide or custom sgRNA library (10⁵–10⁶ guides)

Drug-treated vs. control cell populations

NGS-based dropout or enrichment analysis (MAGeCK / CRISPResso2)

Hit prioritization and pathway enrichment mapping

** Minimum 2 Samples: Drug treated vs untreated

💡 Deliverables: ranked gene lists, volcano plots, pathway analyses, and validation-ready hit data.

FACS-Based Phenotypic Screen

6,999

/sample

***

CRISPR knockout / activation libraries in mammalian cells

Sorting based on fluorescent reporter intensity or antibody staining

Sorted population sequencing and differential sgRNA enrichment

Data integration with single-cell expression or pathway analysis

*** Minimum 2 Samples: Low expression vs high expression

🔬 Deliverables: FACS gating data, differential gene lists, and pathway enrichment reports.

Drug Synthetic Lethal Screen

4,999

/sample

Genome-wide or custom sgRNA library (10⁵–10⁶ guides)

Drug-treated vs. control cell populations

NGS-based dropout or enrichment analysis (MAGeCK / CRISPResso2)

Hit prioritization and pathway enrichment mapping

** Minimum 2 Samples: Drug treated vs untreated

💡 Deliverables: ranked gene lists, volcano plots, pathway analyses, and validation-ready hit data.

FACS-Based Phenotypic Screen

6,999

/sample

***

CRISPR knockout / activation libraries in mammalian cells

Sorting based on fluorescent reporter intensity or antibody staining

Sorted population sequencing and differential sgRNA enrichment

Data integration with single-cell expression or pathway analysis

*** Minimum 2 Samples: Low expression vs high expression

🔬 Deliverables: FACS gating data, differential gene lists, and pathway enrichment reports.

Individual Pricing

Library Preparation, Sequencing & Data Analysis

gDNA extraction, PCR amplification of sgRNA regions, Illumina sequencing, and read count matrix generation.

1,999

/sample

2–4 weeks turnaround time

NGS-based dropout or enrichment analysis (MAGeCK / CRISPResso2)

Hit prioritization and pathway enrichment mapping

💡 Deliverables: Raw & processed NGS data, ranked gene lists, volcano plots, pathway analyses, and validation-ready hit data.

Custom CRISPR Library
Construction

Custom pooled library cloning (genome-wide or targeted); QC by NGS and representation metrics.

3,999

/library

3–4 weeks turnaround time

Genome-wide or custom sgRNA library (12K guides)

Applications: Synthetic lethality • Drug-response modifiers • Immune signaling drivers

🔬 Deliverables: 100 ug of DNA Library in lentiviral backbone with Raw & processed NGS data with representation metrics

FAQ

1. What types of CRISPR pooled screens do you support?

2. What are the recommended experimental designs for drug–gene interaction screens?

3. What multiplicity of infection (MOI) do you use for pooled libraries?

4. What sgRNA expression systems and promoters do you support?

5. How do you ensure consistent Cas9 or dCas9 expression across cell populations?

6. What are typical cell numbers and coverage requirements?

7. Can you perform screens in primary or difficult-to-transduce cells?

8. What libraries do you offer?

9. How do you validate library representation prior to screening?

10. Do you support dual-sgRNA or barcoded libraries?

11. What selection strategies do you support?

12. How do you maintain guide representation throughout culture?

13. What controls are used in CRISPR screens?

14. Can you run screens in co-culture or immune-oncology models?

15. What sequencing depth is required?

16. What computational pipelines do you use for hit analysis?

17. What QC metrics do you provide post-screen?

18. Do you provide hit validation and follow-up assays?

19. What are the total timelines for a full screen?

20. What deliverables will I receive?

Join Us in Advancing Biotech Solutions Together

Join Us in Advancing Biotech Solutions Together

Join Us in Advancing Biotech Solutions Together

Services

Support

Company

Services

Support

Company

+1-(415).463.0365 | info@dunexbio.com |

25801 Industrial Blvd Suite 100, Hayward, CA 94545

Services

Support

Company

25801 Industrial Blvd Suite 100, Hayward, CA 94545

CRISPR Functional Genomics Screening

Step 1 — Library Design & Construction

Step 2 — Cell Line Engineering

Step 3 — Screening Execution

Step 4 — Genomic DNA Extraction

Step 5 — NGS & Quantification

Step 6 — Hit Analysis & Interpretation

Drug Synthetic Lethal Screen

/sample

FACS-Based Phenotypic Screen

/sample

Drug Synthetic Lethal Screen

/sample

FACS-Based Phenotypic Screen

/sample

Drug Synthetic Lethal Screen

/sample

FACS-Based Phenotypic Screen

/sample

Library Preparation, Sequencing & Data Analysis

/sample

Custom CRISPR Library Construction

/library

1. What types of CRISPR pooled screens do you support?

1. What types of CRISPR pooled screens do you support?

1. What types of CRISPR pooled screens do you support?

1. What types of CRISPR pooled screens do you support?

2. What are the recommended experimental designs for drug–gene interaction screens?

2. What are the recommended experimental designs for drug–gene interaction screens?

2. What are the recommended experimental designs for drug–gene interaction screens?

2. What are the recommended experimental designs for drug–gene interaction screens?

3. What multiplicity of infection (MOI) do you use for pooled libraries?

3. What multiplicity of infection (MOI) do you use for pooled libraries?

3. What multiplicity of infection (MOI) do you use for pooled libraries?

3. What multiplicity of infection (MOI) do you use for pooled libraries?

4. What sgRNA expression systems and promoters do you support?

4. What sgRNA expression systems and promoters do you support?

4. What sgRNA expression systems and promoters do you support?

4. What sgRNA expression systems and promoters do you support?

5. How do you ensure consistent Cas9 or dCas9 expression across cell populations?

5. How do you ensure consistent Cas9 or dCas9 expression across cell populations?

5. How do you ensure consistent Cas9 or dCas9 expression across cell populations?

5. How do you ensure consistent Cas9 or dCas9 expression across cell populations?

6. What are typical cell numbers and coverage requirements?

6. What are typical cell numbers and coverage requirements?

6. What are typical cell numbers and coverage requirements?

6. What are typical cell numbers and coverage requirements?

7. Can you perform screens in primary or difficult-to-transduce cells?

7. Can you perform screens in primary or difficult-to-transduce cells?

7. Can you perform screens in primary or difficult-to-transduce cells?

7. Can you perform screens in primary or difficult-to-transduce cells?

8. What libraries do you offer?

8. What libraries do you offer?

8. What libraries do you offer?

8. What libraries do you offer?

9. How do you validate library representation prior to screening?

9. How do you validate library representation prior to screening?

9. How do you validate library representation prior to screening?

9. How do you validate library representation prior to screening?

10. Do you support dual-sgRNA or barcoded libraries?

10. Do you support dual-sgRNA or barcoded libraries?

10. Do you support dual-sgRNA or barcoded libraries?

10. Do you support dual-sgRNA or barcoded libraries?

11. What selection strategies do you support?

11. What selection strategies do you support?

11. What selection strategies do you support?

11. What selection strategies do you support?

12. How do you maintain guide representation throughout culture?

12. How do you maintain guide representation throughout culture?

12. How do you maintain guide representation throughout culture?

12. How do you maintain guide representation throughout culture?

13. What controls are used in CRISPR screens?

13. What controls are used in CRISPR screens?

13. What controls are used in CRISPR screens?

13. What controls are used in CRISPR screens?

14. Can you run screens in co-culture or immune-oncology models?

14. Can you run screens in co-culture or immune-oncology models?

14. Can you run screens in co-culture or immune-oncology models?

14. Can you run screens in co-culture or immune-oncology models?

15. What sequencing depth is required?

Custom CRISPR Library
Construction